We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.
- Authors
Lewis-Wolfson, Temeka Dawn; Joyner, Kayla Rena
- Abstract
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The authors raised concerns for any potentially confounding factors such as additional medications, individual illness, and co-morbidities as well as consideration of preceding asymptomatic COVID-19. We thank the authors of the letter to the editor for their comments on our recent publication, "Baricitinib Versus Tocilizumab for the treatment of Moderate to Severe COVID-19."[1] While the authors of both letters agree our study found no difference in the composite outcome, the first reply from Mungmunpuntipantip and Wiwanitkit noted possible clinical implications to consider when choosing baricitinib or tocilizumab.
- Subjects
BARICITINIB; COVID-19; TOCILIZUMAB; HEALTH facilities; INTERLEUKIN-6 receptors
- Publication
Annals of Pharmacotherapy, 2023, Vol 57, Issue 9, p1118
- ISSN
1060-0280
- Publication type
Article
- DOI
10.1177/10600280221144936